News Details View all news Moderna and Australia Announce Collaboration to Bring mRNA Manufacturing to Australia
December, 13, 2021
Up to 100 million mRNA vaccine doses could be produced in Australia each year
Manufacturing facility to provide access to domestically manufactured vaccines against respiratory viruses
Collaboration will support Australia with direct access to rapid pandemic response capabilities
CAMRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement in principle with the Australian Government to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility in Victoria, Australia including access to Moderna’s mRNA development engine. The contemplated framework would build the foundation to support Australia with direct access to rapid pandemic response capabilities and to provide access to Moderna’s vaccines in development for respiratory viruses. Moderna and the Australian government are committed to finalize the agreement.
“I would like to thank the Australian and Victorian Governments for their collaboration and partnership,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We are committed to global public health and while we are still responding to this pandemic, we also want to ensure we and society learn from it. As Moderna expands internationally, we are pleased to bring local mRNA manufacturing to Australia. We believe that this sustainable national business model will have global impact and implications.”
Moderna is committed to working with governments, health care professionals and other key stakeholders to meet the challenges of the COVID-19 pandemic and future pathogens. Moderna expects to invest in a state-of-the-art manufacturing facility for the production of mRNA vaccines with the collaboration of the Commonwealth and Victorian Governments. The collaboration aims to provide Australians with access to a domestically manufactured portfolio of mRNA vaccines against respiratory viruses, including COVID-19, seasonal influenza, respiratory syncytial virus (RSV) and potential other vaccines, pending licensure. Moderna expects that up to 100 million vaccine doses could be produced in Australia each year. The facility is intended to also be activated on an urgent basis to support Australia with direct access to rapid pandemic response capabilities. The Company is in discussion with other governments about potential collaborations built on a similar model.
“We are excited to expand our presence and continue our long-term collaboration with the Australian and Victorian Governments,” said Michael Azrak, Moderna’s General Manager of Australia. “We look forward to completing the necessary discussions and starting work to develop onshore mRNA manufacturing capability here in Australia.”
The agreement was announced today in Victoria by the Hon. Scott Morrison, MP Prime Minister of Australia.
About Moderna
In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company’s collaboration with the Australian government to develop mRNA manufacturing facilities in Australia; the finalization of the agreement with the government of Australia; the types of medicines to be manufactured at the facility and pandemic response capabilities; and potential collaborations with other governments to develop mRNA manufacturing capabilities globally. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.
(20min delay)